Our commercially validated ENHANZE® drug delivery technology, based on our proprietary enzyme rHuPH20, is used to facilitate the delivery of injected drugs and fluids. When co-formulated with other drugs, ENHANZE® has the potential to reduce treatment burden for patients, including potentially reducing treatment administration from hours-long IV infusions to SC injections delivered in minutes.
We are currently advancing multiple programs intended to deliver innovative therapies through world class collaborations. Our ENHANZE® technology has been licensed globally to leading pharmaceutical and biotechnology companies including, AbbVie, Alexion, argenx, Baxalta, Bristol-Myers Squibb, Horizon Therapeutics, Janssen, Lilly, Pfizer, Roche and ViiV Healthcare.
In addition, we market and commercialize Hylenex® recombinant (hyaluronidase human injection) in the United States, which is indicated as an adjuvant to increase the dispersion and absorption of other injected drugs.